-+ 0.00%
-+ 0.00%
-+ 0.00%

Emergent BioSolutions Sees Q2 Sales $170.000M-$185.000M vs $186.000M Est

Benzinga·04/30/2026 20:33:22
Listen to the news
Emergent BioSolutions (NYSE:EBS) sees Q2 sales of $170.000 million-$185.000 million vs $186.000 million analyst estimate.